Literature DB >> 22186667

Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship.

Euitae Kim1, Oliver D Howes, Bo-Hyung Kim, Jae Min Jeong, Jae Sung Lee, In-Jin Jang, Sang-Goo Shin, Federico E Turkheimer, Shitij Kapur, Jun Soo Kwon.   

Abstract

Positron emission tomography (PET) studies of dopamine receptor occupancy can be used to assess dosing of antipsychotics. Typically, studies of antipsychotics have applied pharmacodynamic (PD) modeling alone to characterize the relationship between antipsychotic dose and its effect on the brain. However, a limitation of this approach is that it does not account for the discrepancy between the time courses of plasma concentration and receptor occupancy by antipsychotics. Combined pharmacokinetic-PD (PK-PD) modeling, by incorporating the time dependence of occupancy, is better suited for the reliable analysis of the concentration-occupancy relationship. To determine the effect of time on the concentration-occupancy relationship as a function of analysis approach, we measured dopamine receptor occupancy after the administration of aripiprazole using [(11)C]raclopride PET and obtained serial measurements of the plasma aripiprazole concentration in 18 volunteers. We then developed a PK-PD model for the relationship, and compared it with conventional approach (PD modeling alone). The hysteresis characteristics were observed in the competitor concentration-occupancy relationship and the value of EC(50) was different according to the analysis approach (EC(50) derived from PD modeling alone=11.1 ng/mL (95% confidence interval (CI)=10.1 to 12.1); while that derived from combined PK-PD modeling=8.63 ng/mL (95% CI=7.75 to 9.51)). This finding suggests that PK-PD modeling is required to obtain reliable prediction of brain occupancy by antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22186667      PMCID: PMC3318151          DOI: 10.1038/jcbfm.2011.180

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  36 in total

1.  Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.

Authors:  S Kapur; P Seeman
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Significant dissociation of brain and plasma kinetics with antipsychotics.

Authors:  Johannes Tauscher; C Jones; G Remington; R B Zipursky; S Kapur
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

3.  Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.

Authors:  Rik de Greef; Alan Maloney; Per Olsson-Gisleskog; Joep Schoemaker; John Panagides
Journal:  AAPS J       Date:  2010-12-24       Impact factor: 4.009

4.  Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.

Authors:  Sergio Abanades; Jasper van der Aart; Julien A R Barletta; Carmine Marzano; Graham E Searle; Cristian A Salinas; Javaad J Ahmad; Richard R Reiley; Sabina Pampols-Maso; Stefano Zamuner; Vincent J Cunningham; Eugenii A Rabiner; Marc A Laruelle; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-13       Impact factor: 6.200

Review 5.  Molecular imaging in drug development.

Authors:  Jürgen K Willmann; Nicholas van Bruggen; Ludger M Dinkelborg; Sanjiv S Gambhir
Journal:  Nat Rev Drug Discov       Date:  2008-07       Impact factor: 84.694

6.  Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice.

Authors:  Katrin M Kirschbaum; Manfred Uhr; David Holthoewer; Christian Namendorf; Claus Pietrzik; Christoph Hiemke; Ulrich Schmitt
Journal:  Neuropharmacology       Date:  2010-07-03       Impact factor: 5.250

7.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

Authors:  S Kapur; R Zipursky; C Jones; G Remington; S Houle
Journal:  Am J Psychiatry       Date:  2000-04       Impact factor: 18.112

8.  Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy--a simulation study based on experimental data.

Authors:  H Olsson; L Farde
Journal:  Neuroimage       Date:  2001-10       Impact factor: 6.556

9.  Application of PAMPA-models to predict BBB permeability including efflux ratio, plasma protein binding and physicochemical parameters.

Authors:  Jurgen Mensch; Libuse Jaroskova; Wendy Sanderson; Anouche Melis; Claire Mackie; Geert Verreck; Marcus E Brewster; Patrick Augustijns
Journal:  Int J Pharm       Date:  2010-08-16       Impact factor: 5.875

Review 10.  Functional neuroimaging in schizophrenia: diagnosis and drug discovery.

Authors:  Philip McGuire; Oliver D Howes; James Stone; Paolo Fusar-Poli
Journal:  Trends Pharmacol Sci       Date:  2008-01-09       Impact factor: 14.819

View more
  15 in total

1.  In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.

Authors:  I Loryan; E Melander; M Svensson; M Payan; F König; B Jansson; M Hammarlund-Udenaes
Journal:  Mol Psychiatry       Date:  2016-01-26       Impact factor: 15.992

2.  Simulation of PET scan timings for receptor occupancy studies of CNS drugs: a simple fixed-time design performed as well as scattered time point designs.

Authors:  Jongtae Lee; Sangil Jeon; Taegon Hong; Seunghoon Han; Dong-Seok Yim
Journal:  Eur J Clin Pharmacol       Date:  2015-09-09       Impact factor: 2.953

Review 3.  Contrast-enhanced dual mode imaging: photoacoustic imaging plus more.

Authors:  Sungjo Park; Unsang Jung; Seunghyun Lee; Donghyun Lee; Chulhong Kim
Journal:  Biomed Eng Lett       Date:  2017-01-23

4.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

Authors:  Nithya Srinivas; Kaitlyn Maffuid; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

6.  Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study.

Authors:  Euitae Kim; Oliver D Howes; Bo-Hyung Kim; Myong-Wuk Chon; Seongho Seo; Federico E Turkheimer; Jae Sung Lee; Yun-Sang Lee; Jun Soo Kwon
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

Review 7.  Translational PK-PD modeling in pain.

Authors:  Ashraf Yassen; Paul Passier; Yasuhisa Furuichi; Albert Dahan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

8.  The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole.

Authors:  Euitae Kim; Oliver D Howes; Federico E Turkheimer; Bo-Hyung Kim; Jae Min Jeong; Ji Who Kim; Jae Sung Lee; In-Jin Jang; Sang-Goo Shin; Shitij Kapur; Jun Soo Kwon
Journal:  Psychopharmacology (Berl)       Date:  2012-12-28       Impact factor: 4.530

9.  Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study.

Authors:  Oliver D Howes; Matthew Williams; Kemal Ibrahim; Garret Leung; Alice Egerton; Philip K McGuire; Federico Turkheimer
Journal:  Brain       Date:  2013-10-03       Impact factor: 13.501

Review 10.  Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.

Authors:  I Bonoldi; O D Howes
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.